This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Verso, M. Articles by Agnelli, G. Search for Related Content PubMed PubMed Citation Articles by Verso, M. Articles by Agnelli, G.

Venous Thromboembolism Associated With Long-Term Use of Central Venous Catheters in Cancer Patients

From the Division of Internal and Cardiovascular Medicine, Department of Internal Medicine, University of Perugia, Perugia, Italy.

Address reprint requests to Melina Verso, MD, Sezione di Medicina Interna e Cardiovascolare, Dipartimento di Medicina Interna, Università di Perugia, Via Enrico dal Pozzo, 06123 Perugia, Italy; e-mail: agnellig{at}unipg.it.

Long-term central venous catheters (CVCs) have considerably improved the management of cancer patients because they facilitate chemotherapy, transfusions, parenteral nutrition, and blood sampling. However, the use of long-term CVCs, especially for chemotherapy, has been associated with the occurrence of upper-limb deep venous thrombosis (UL-DVT). The incidence of clinically overt UL-DVT related to CVCs has been reported to vary between 0.3% and 28.3%. The incidence of CVC-related UL-DVT screened by venography reportedly varies between 27% and 66%. The incidence of clinically overt pulmonary embolism (PE) in patients with CVC-related UL-DVT ranges from 15% to 25%, but an autopsy-proven PE rate of up to 50% has been reported. Vessel injury caused by the procedure of CVC insertion, venous stasis caused by the indwelling CVC, and cancer-related hypercoagulability are the main pathogenetic factors for CVC-related venous thromboembolism (VTE). Several studies have assessed the benefit of the prophylaxis of UL-DVT after CVC insertion in cancer patients. According to the results of these studies, prophylaxis with low molecular weight heparin or a low fixed dose of warfarin has been recently proposed. However, the limitations of the experimental design of the prophylactic studies do not allow definitive recommendations. The recommended therapy for UL-DVT associated with CVC is based on anticoagulant therapy with or without catheter removal. This review focuses on the epidemiology, pathogenesis, diagnosis, prevention, and treatment of VTE in cancer patients with long-term CVC.

This article has been cited by other articles:

				J. D. Paauw, H. Borders, N. Ingalls, S. Boomstra, S. Lambke, B. Fedeson, A. Goldsmith, and A. T. Davis The Incidence of PICC Line-Associated Thrombosis With and Without the Use of Prophylactic Anticoagulants JPEN J Parenter Enteral Nutr, July 1, 2008; 32(4): 443 - 447. [Abstract] [Full Text] [PDF]

				N. F. Aykan and E. Idelevich The role of UFT in advanced gastric cancer Ann. Onc., June 1, 2008; 19(6): 1045 - 1052. [Abstract] [Full Text] [PDF]

				D. G. Haller, J. Cassidy, S. J. Clarke, D. Cunningham, E. Van Cutsem, P. M. Hoff, M. L. Rothenberg, L. B. Saltz, H.-J. Schmoll, C. Allegra, et al. Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines J. Clin. Oncol., May 1, 2008; 26(13): 2118 - 2123. [Abstract] [Full Text] [PDF]

				S. Vescia, A. K. Baumgartner, V. R. Jacobs, M. Kiechle-Bahat, A. Rody, S. Loibl, and N. Harbeck Management of venous port systems in oncology: a review of current evidence Ann. Onc., January 1, 2008; 19(1): 9 - 15. [Abstract] [Full Text] [PDF]

				D Fagnani, R Franchi, C Porta, P Pugliese, K Borgonovo, A Bertolini, M Duro, A Ardizzoia, V Filipazzi, L Isa, et al. Thrombosis-related complications and mortality in cancer patients with central venous devices: an observational study on the effect of antithrombotic prophylaxis Ann. Onc., March 1, 2007; 18(3): 551 - 555. [Abstract] [Full Text] [PDF]

				L. B. Michaud, J. P. Karpinski, K. L. Jones, and J. Espirito Dietary supplements in patients with cancer: Risks and key concepts, part 1 Am. J. Health Syst. Pharm., February 15, 2007; 64(4): 369 - 381. [Abstract] [Full Text] [PDF]

				J. M. Journeycake and G. R. Buchanan Catheter-Related Deep Venous Thrombosis and Other Catheter Complications in Children With Cancer J. Clin. Oncol., October 1, 2006; 24(28): 4575 - 4580. [Abstract] [Full Text] [PDF]

				D. Gaitini, N. Beck-Razi, N. Haim, and B. Brenner Prevalence of Upper Extremity Deep Venous Thrombosis Diagnosed by Color Doppler Duplex Sonography in Cancer Patients With Central Venous Catheters. J. Ultrasound Med., October 1, 2006; 25(10): 1297 - 1303. [Abstract] [Full Text] [PDF]

				A. Y.Y. Lee, M. N. Levine, G. Butler, C. Webb, L. Costantini, C. Gu, and J. A. Julian Incidence, Risk Factors, and Outcomes of Catheter-Related Thrombosis in Adult Patients With Cancer J. Clin. Oncol., March 20, 2006; 24(9): 1404 - 1408. [Abstract] [Full Text] [PDF]

				R. Glynne-Jones, J. Dunst, and D. Sebag-Montefiore The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been? Ann. Onc., March 1, 2006; 17(3): 361 - 371. [Abstract] [Full Text] [PDF]

				C.-H. Kohne and G. Folprecht On prejudice and facts and choices Ann. Onc., February 1, 2006; 17(2): 185 - 187. [Full Text] [PDF]

				M. Karthaus, A. Kretzschmar, H. Kroning, M. Biakhov, D. Irwin, N. Marschner, C. Slabber, G. Fountzilas, A. Garin, N. G. F. Abecasis, et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial Ann. Onc., February 1, 2006; 17(2): 289 - 296. [Abstract] [Full Text] [PDF]

				C. Twelves, S. Gollins, R. Grieve, and L. Samuel A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer Ann. Onc., February 1, 2006; 17(2): 239 - 245. [Abstract] [Full Text] [PDF]

				E. A. Krzywda and D. A. Andris Twenty-five Years of Advances in Vascular Access: Bridging Research to Clinical Practice Nutr Clin Pract, December 1, 2005; 20(6): 597 - 606. [Abstract] [Full Text] [PDF]

				D. T. Alexandrescu and P. H. Wiernik Cutaneous Manifestations of a Catheter-Related Thrombus Arch Dermatol, August 1, 2005; 141(8): 1049 - 1049. [Full Text] [PDF]

				M. Verso, G. Agnelli, S. Bertoglio, F. C. Di Somma, F. Paoletti, W. Ageno, M. Bazzan, P. Parise, R. Quintavalla, E. Naglieri, et al. Enoxaparin for the Prevention of Venous Thromboembolism Associated With Central Vein Catheter: A Double-Blind, Placebo-Controlled, Randomized Study in Cancer Patients J. Clin. Oncol., June 20, 2005; 23(18): 4057 - 4062. [Abstract] [Full Text] [PDF]

				M. Levine and A.K. Kakkar Catheter-Associated Thrombosis: Thromboprophylaxis or Not? J. Clin. Oncol., June 20, 2005; 23(18): 4006 - 4008. [Full Text] [PDF]

				J. Feliu, P. Escudero, F. Llosa, M. Bolanos, J.-M. Vicent, A. Yubero, J.-J. Sanz-Lacalle, R. Lopez, L. Lopez-Gomez, E. Casado, et al. Capecitabine As First-Line Treatment for Patients Older Than 70 Years With Metastatic Colorectal Cancer: An Oncopaz Cooperative Group Study J. Clin. Oncol., May 1, 2005; 23(13): 3104 - 3111. [Abstract] [Full Text] [PDF]

				A. Falanga and L. Zacharski Deep vein thrombosis in cancer: the scale of the problem and approaches to management Ann. Onc., May 1, 2005; 16(5): 696 - 701. [Abstract] [Full Text] [PDF]

				H. V. Joffe, N. Kucher, V. F. Tapson, S. Z. Goldhaber, and for the Deep Vein Thrombosis (DVT) FREE Steering C Upper-Extremity Deep Vein Thrombosis: A Prospective Registry of 592 Patients Circulation, September 21, 2004; 110(12): 1605 - 1611. [Abstract] [Full Text] [PDF]

				P. Monagle, A. Chan, P. Massicotte, E. Chalmers, and A. D. Michelson Antithrombotic Therapy in Children*: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 645S - 687S. [Abstract] [Full Text] [PDF]